A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo.
In animal models frakefamide (FF) is a potent analgesic that acts as a peripheral active mu-selective receptor agonist. In this double-blind, randomized, double dummy four-way crossover study in 12 healthy male subjects, we investigated the effects on resting ventilation of FF and 2 dose levels of morphine compared with placebo. Each drug was infused for 6 h. The subjects received 1.22 mg/kg FF, 0.43 mg/kg morphine (M-large), and 0.11 mg/kg morphine (M-small). Sodium chloride 9 mg/mL was used as placebo. Ventilation was measured by pneumotachography and inline capnography. Blood was collected and plasma concentrations of FF and morphine and its metabolites were analyzed. Within 15 min after administration of FF all subjects complained of a transient myalgia, which disappeared within 30 min. At target measurement (335 min), there were no differences in tidal volume among the groups. Respiratory rates were, however, slower in the two M-groups (P < 0.05 in M-small and P < 0.001 in M-large) compared with FF and placebo. Minute volume was significantly less in the M-large group compared with the FF (P < 0.01) and placebo (P < 0.01) groups. This difference was reflected by an elevated ETco(2) in the M-large group (P < 0.01). We conclude that, during resting ventilation, FF, unlike morphine, did not cause central respiratory depression. This suggests that FF has only peripheral mu-opioid agonist activity in humans.
Modalen
Åsa Österlund
ÅÖ
Departments of Anesthesiology and Intensive Care, Danderyds Hospital and Karolinska Institute, Stockholm.
Quiding
Hans
H
Frey
Joana
J
Westman
Lars
L
Lindahl
Sten
S
D000293:Adolescent; D000328:Adult; D000701:Analgesics, Opioid / Q000097:blood / Q000494:pharmacology*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000097:blood / Q000494:pharmacology*; D009842:Oligopeptides / Q000097:blood / Q000494:pharmacology*; D017450:Receptors, Opioid, mu / Q000819:agonists*; D012119:Respiration / Q000187:drug effects*
D000701:Analgesics, Opioid; D009842:Oligopeptides; D017450:Receptors, Opioid, mu; D009020:Morphine; C497770:frakefamide
Carr DB, Goudas LC. Acute pain. Lancet 1999;353:2051–8.
Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002;18:3–13.
Shannon HE, Lutz EA. Comparison of the peripheral and central effects of the opioid agonist loperamide and morphine in the formalin test in rats. Neuropharmacology 2001;42:253–61.
Stein C. Peripheral analgesic actions of opioids. J Pain Symptom Manage 1991;6:119–24.
Stein C, Machelska H, Binder W, et al. Peripheral opioid analgesia. Curr Opin Pharmacol 2001;1:62–5.
Alari L, Payza K, Ekström G. Frakefamide-a peripheral active μ-selective receptor agonist [abstract]. 10th World Congress on Pain, San Diego. 2002;1508:P56.
Hägglöf B, Molnar V, Jonzon B. Tolerability, pharmacodynamics and pharmacokinetics of a single intravenous doses of a new peripheral μ-opioid agonist, frakefamide, in healthy subjects [abstract]. 10th World Congress on Pain, San Diego. 2002;601:P235.
van de Waterbeemd H, Camenisch G, Folkers G, et al. Estimation of blood-brain-barrier crossing of drugs using molecular size and shape and H-bonding descriptors. J Drug Targeting 1998;6:151–65.
Wood A. New method of treating neuralgia by the direct application of opioids to the painful points. Edinburgh Med Surg J 1985;82:265–81.
Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg 1993;76:182–91.
Shook JE, Watkins WD, Camporesi EM. State of the art: differential roles of opioid receptors in respiration, respiratory disease and opiate-induced respiratory depression. Am Rev Respir Dis 1990;142:895–909.
Harrison C, Lambert DG. Opioid and nociceptin receptors story of a growing and maturing family. R Coll Anaesthetists Newsletter 1999;49:243–6.